For the Inventor, By the Inventor

Enter assignee name

Leiden, Netherlands

Proqr Therapeutics Ii B.v.

USPTO Granted Patents = 24

CIPO Patents = 8

EPO Patents = 7

Trademarks = 4

Forward Citations = 51

Loading Chart...

Loading Chart...

29 inventors (with patents filed for the assignee):

Janne Juha Turunen (13 out of 13 patents)

Bart Klein (9 out of 9 patents)

Lenka Van Sint Fiet (8 out of 8 patents)

4. Hee Lam Chan (7 out of 7 patents)

5. Julien Auguste Germain Boudet (5 out of 5 patents)

6. Antti Aalto (4 out of 4 patents)

7. Hester Catharina Van Diepen (4 out of 4 patents)

8. Gerardus Johannes Platenburg (3 out of 7 patents)

9. Petra Geziena De Bruijn (3 out of 3 patents)

10. Roxana Simona Redis (3 out of 3 patents)

11. Patricia Coromoto Biasutto (3 out of 3 patents)

12. Peter Adamson (2 out of 2 patents)

13. Daniel Anton De Boer (2 out of 2 patents)

14. Tita Ritsema (2 out of 2 patents)

15. Kalyana Chakravarthi Dulla (2 out of 2 patents)

24 patents: Sort by Forward Citations

1. 12398393 - RNA-editing oligonucleotides for the treatment of usher syndrome (2025-08-26),

2. 12275937 - Stereospecific linkages in RNA editing oligonucleotides (2025-04-14),

3. 12203072 - Chemically modified single-stranded rna-editing oligonucleotides (2025-01-21),

4. 12180471 - Antisense oligonucleotides for the treatment of Stargardt disease (2024-12-31),

5. 12018257 - Single-stranded RNA-editing oligonucleotides (2024-06-25),

6. 11920132 - Oligonucleotide therapy for Leber congenital amaurosis (2024-03-05),

7. 11866702 - Nucleic acid molecules for pseudouridylation (2024-01-09),

8. 11851656 - Chemically modified single-stranded RNA-editing oligonucleotides (2023-12-26),

9. 11781134 - Targeted RNA editing (2023-10-10),

10. 11649454 - Single-stranded RNA-editing oligonucleotides (2023-05-16),

11. 11479771 - Antisense oligonucleotides for the treatment of eye disease (2022-10-25),

12. 11274300 - Oligonucleotide complexes for use in RNA editing (2022-03-15),

13. 11123360 - Oligonucleotides to treat eye disease (2021-09-21),

14. 10988763 - Single-stranded RNA-editing oligonucleotides (2021-04-27),

15. 10941402 - Chemically modified single-stranded RNA-editing oligonucleotides (2021-03-09),

ProQR Therapeutics II B.V. is a biotechnology company that focuses on the development of RNA therapies for serious genetic diseases. The company utilizes its proprietary RNA platform to create transformative treatments for patients with diseases such as cystic fibrosis, Leber's congenital amaurosis, and severe genetic disorders. ProQR Therapeutics II B.V. collaborates with academic institutions, pharmaceutical partners, and patient organizations to advance its innovative therapies. For more information, please visit their website.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 9 2025

24 Patents

#8 in Leiden

#292 in Netherlands

#25,825 in the World

Leiden, Netherlands

Proqr Therapeutics Ii B.v.

Forward Citations = 51

29 inventors:

Janne Juha Turunen (13 out of 13 patents)

Bart Klein (9 out of 9 patents)

Lenka Van Sint Fiet (8 out of 8 patents)

4. Hee Lam Chan (7 out of 7 patents)

5. Julien Auguste Germain Boudet (5 out of 5 patents)

Please report any incorrect information to support@idiyas.com

Loading…